drugset / Trial / NCT00479856
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of lapatinib in combination with chemotherapy (capecitabine, docetaxel, nab-paclitaxel) in subjects with ErbB2-overexpressing breast cancer whose disease has progressed during or within 12 months after completion of trastuzumab-containing therapy in the neoadjuvant or adjuvant setting.
Timeline
- Start
- 2007-11
- Primary completion
- 2009-09
- Completion
- 2010-03
Outcome
Outcome not reported
Stopped: “Study was terminated due to difficulty in identifying eligible subjects”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lapatinib | Small molecule | — | — |
| Background | Capecitabine | Small molecule | — | — |
| Background | Docetaxel | Small molecule | — | — |
| Background | Nab-paclitaxel | Small molecule | — | — |